What’s the Best Way to Identify Mild Cognitive Impairment and Early Alzheimer’s Disease?

Host: Ashley Baker, MSN, PMHNP
Guest: Stanley N. Caroff, MD

Catatonia is a neuropsychiatric condition characterized by disturbances in psychomotor function, stemming from various disorders impacting brain function. And while catatonia is not specifically related to schizophrenia alone, it’s important to know how to recognize and treat schizophrenic patients with catatonic symptoms. That’s why psychiatric nurse practitioner Ashley Baker speaks with Dr. Stanley Caroff about his research focusing on the management of schizophrenia with catatonic symptoms. Dr. Caroff is an Emeritus Professor of Psychiatry at the University of Pennsylvania Perelman School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jagan Pillai, MD, PhD

Cerebral amyloid angiopathy (CAA) is a common neurological change that frequently coexists with other pathologies like Alzheimer's disease and Lewy body dementia, which led a team of researchers to investigate the risk factors and prevalence of CAA. The study found that not only is age a risk factor for CAA, but CAA is also seen in patients with Lew body pathology alone and in patients with both Alzheimer's disease and Lewy body pathology. Dive further into the findings with Dr. Charles Turck and Dr. Jagan Pillai, a behavioral neurologist at Cleveland Clinic Lou Ruvo Center for Brain Health.

Guest: Daniel Harrison, MD

Adaptive optics is a promising tool for studying MS-related changes in the retina at a cellular level, providing valuable insights into the disease's progression and potential treatments. Dive further into this line of research with Dr. Daniel Harrison, an Associate Professor of Neurology and the Director of the Division of Multiple Sclerosis and Neuroimmunology at the University of Maryland who presented this research at the 2024 ACTRIMS Forum.

Host: Heidi M. Munger Clary, MD, MPH
Guest: Jay Salpekar, MD, FANPA

A crucial aspect of epilepsy care that often goes underappreciated is the intersection of epilepsy and depression. Join Drs. Munger Clary and Salpekar, leading experts in the field, as they raise awareness about the high prevalence of comorbid mental health disorders, particularly depression, among epilepsy patients. Together, they explore the bidirectional relationship between epilepsy and depression, emphasizing the importance of early detection and comprehensive treatment. They’ll also cover implantable therapies, specifically vagal nerve stimulation devices, as potential tools to manage both epilepsy and depression.

Host: Andrew Wilner, MD, FACP, FAAN
Guest: Marcus E. Peter, PhD

Death induced by survival gene elimination (DISE) is a cell death mechanism mediated by short RNAs. And according to a recent study, there may be a correlation between toxic DISE, DNA damage, and neuronal cell death in patients with Alzheimer’s disease. Learn more about the study’s findings and potential implications with Dr. Andrew Wilner and Dr. Marcus Peter, Professor of Medicine in the Division of Hematology and Oncology as well as a Professor of Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine in Chicago.

Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Jini Naidoo, PhD

According to new research featured in Aging Biology, a treatment involving 4-phenylubrate (PBA) may delay or reverse signs of Alzheimer’s disease. To learn more, Dr. Andrew Wilner dives into the results and potential implications of this mouse-model study with Dr. Jini Naidoo, Research Associate Professor of Sleep Medicine at the Perelman School of Medicine at the University of Pennsylvania.

Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP

Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.

Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise

Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP

Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.

Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise

Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP

Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.

Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise

Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP

Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.

Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise